HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Methylphenidate Hydrochloride

HCID 9280
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
298-59-9
Standard SMILES
COC(=O)C(c1ccccc1)C1CCCCN1.Cl
InChIKey
JUMYIBMBTDDLNG-UHFFFAOYSA-N
Molecular formula
C14H19NO2.ClH
Average molar mass
269.77 g/mol
Monoisotopic mass
269.1182566

Overview

Methylphenidate hydrochloride is an odorless white crystalline powder. Metallic taste. Solutions are acid to litmus. Absence of general acid/base catalysis. (NTP, 1992)

Names & identifiers

Preferred name
Methylphenidate Hydrochloride
IUPAC
methyl 2-phenyl-2-piperidin-2-ylacetate;hydrochloride

Names & synonyms

METHYLPHENIDATE HYDROCHLORIDE298-59-9Methylphenidate HClRitalin SRMethylin ERRitalin LARitalin-SRMetadateQuillivant XRQuilliChew ERRitalinMetadate CD
Show more names
QuillichewQuillivantAptensioFoquestDTXSID8020886Metadate ERMethylphenidylacetate hydrochlorideOros mph

Database identifiers

CAS
298-59-9
PubChem CID
9280
DTXSID
DTXSID8020886
ChEMBL
CHEMBL1722
EC Number
206-065-3

Properties

Computed structural properties

Topological polar surface area
38.3 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
3
Rotatable bonds
4
Heavy atoms
18
Formal charge
0
Complexity
249

Experimental & physicochemical properties

Solubilitygreater than or equal to 100 mg/mL at 68 °F (NTP, 1992)
Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point435 to 439 °F (NTP, 1992)
Physical DescriptionMethylphenidate hydrochloride is an odorless white crystalline powder. Metallic taste. Solutions are acid to litmus. Absence of general acid/base catalysis. (NTP, 1992)
Collision Cross Section152.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (98.4%): Harmful if swallowed [Warning Acute toxicity, oral]

P233, P260, P261, P264, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P319, P321, P330, P333+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 64 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationMethylphenidate hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride: Environment tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1 item

SYMPTOMS: Symptoms of exposure to this chemical may include nausea, vomiting, nervousness, insomnia, dizziness, headache, blood pressure and pulse changes, anorexia, palpitations, dyskinesia, drowsiness, tachycardia, angina, cardiac arrhythmia, abdominal pain and weight loss. It may also cause hypersensitivity, including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis and thrombocytopenia purpura. Exposure to this compound may cause multiple small retinal emboli and a rise in ocular pressure in glaucomatous patients. Other symptoms include difficulties with accommodation and blurring of vision, Tourette`s syndrome, toxic psychosis, leukopenia, anemia, scalp hair loss, agitation, tremors, hyperreflexia, muscle twitching, convulsions which may be followed by coma, euphoria, confusion, hallucinations, delirium, sweating, flushing, hyperpyrexia, hypertension, mydriasis and dryness of mucous membranes. It also causes dryness of the mouth, constipation or diarrhea, difficulty in micturition, restlessness, changes in libido, talkativeness, disorientation, aggressive behavior, fatigue, mental depression which may be followed by convulsions and coma, aplastic anemia, acute conjunctivitis, pancytopenia, hypotension, angioneuroti edema, paranoid psychosis, lethargy, sleepiness and akathisia.

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Methylphenidate is hepatically metabolized. More specifically, it is rapidly and extensively metabolized by carboxylesterase CES1A1. Via this enzyme, methylphenidate undergoes de-esterification to ritalinic acid (a-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity. Route of Elimination: After oral administration of an immediate release formulation of methylphenidate, 78%-97% of the dose is excreted in the urine and 1%-3% in the feces in the form of metabolites within 48-96 hours. Only small quantities (<1%) of unchanged methylphenidate appear in the urine. Most of the dose is excreted in the urine as ritalinic acid (60%-86%), the remainder being accounted for by minor metabolites. Half Life: d-methylphenidate = 3-4 hours; l-methylphenidate = 1-3 hours; Ritalinic acid = 3-4 hours;

FDA Pharmacological Classification · 6 items

METHYLPHENIDATE HCL

Central Nervous System Stimulation [PE]; Central Nervous System Stimulant [EPC]

METHYLPHENIDATE HYDROCHLORIDE

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

METHYLPHENIDATE HYDROCHLORIDE EXTENDED RELEASE

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

MeSH Pharmacological Classification · 2 items

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Uses & manufacturing

Uses · 1 item

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Related reactions

41 records
New reaction record
HRID 219483 reaction equation
HRID 219483As reactant
HRID 241543 reaction equation
HRID 241543As reactant
HRID 241544 reaction equation
HRID 241544As reactant
HRID 242138 reaction equation
HRID 242138As reactant
HRID 242139 reaction equation
HRID 242139As reactant
HRID 333511 reaction equation
HRID 333511As reactant
HRID 403096 reaction equation
HRID 403096As reactant
HRID 570081 reaction equation
HRID 570081As reactant
PreviousPage 1 of 6

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Reactive GroupEsters, Sulfate Esters, Phosphate Esters, Thiophosphate Esters, and Borate Esters
Reactivity ProfileMETHYLPHENIDATE HYDROCHLORIDE is incompatible with alkalis and solutions of barbiturates (NTP, 1992). Undergoes typical ester hydrolysis in aqueous solutions at 176 °F.
Air and Water ReactionsWater soluble.
Hazard Classes and CategoriesAcute Tox. 4 (98.4%)

Safety & protection

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 item

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Isolation and EvacuationExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Personal Protective Equipment (PPE) · 1 item

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxicology

Treatment · 1 item

Treatment consists of appropriate supportive measures. The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. Gastric contents may be evacuated by gastric lavage. In the presence of severe intoxication, use a carefully titrated dosage of a short-acting barbiturate before performing gastric lavage. Other measures to detoxify the gut include administration of activated charcoal and a cathartic. Intensive care must be provided to maintain adequate circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia. (L1712)

Health Effects · 1 item

Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion.

Exposure Routes · 1 item

Oral. Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22&#177;8% for d-methylphenidate and 5&#177;3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically.

Toxicity Summary · 1 item

Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result.

Signs and Symptoms · 1 item

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes.

Carcinogen Classification · 6 items

Methylphenidate Hydrochloride

TR-439: Toxicology and Carcinogenesis Studies of Methylphenidate Hydrochloride (CASRN 298-59-9) in F344/N Rats and B6C3F1 Mice (Feed Studies) (1995 )

06/22/93

No Evidence

No Evidence

Some Evidence

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Methylphenidate hydrochloride

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 190 mg/kg (oral, mice)